# EDGAR Filing Document

**Accession Number:** 0001776353
**File Stem:** 0000921895-25-002596
**Filing Date:** 2025-9
**Character Count:** 35228
**Document Hash:** dbc9c5887675613d56a3032b99294cec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-25-002596.hdr.sgml**: 20250919

**ACCESSION NUMBER**: 0000921895-25-002596

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20250919

**DATE AS OF CHANGE**: 20250919

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARTELO BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001621221
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 331220924
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90653
- **FILM NUMBER:** 251325605

**BUSINESS ADDRESS:**
- **STREET 1:** 505 LOMAS SANTA FE, SUITE 160
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
- **BUSINESS PHONE:** 858-925-7049

**MAIL ADDRESS:**
- **STREET 1:** 505 LOMAS SANTA FE, SUITE 160
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REACTIVE MEDICAL INC.
- **DATE OF NAME CHANGE:** 20170207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KNIGHT KNOX DEVELOPMENT CORP.
- **DATE OF NAME CHANGE:** 20141001
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Farb Daniel Stuart
- **CENTRAL INDEX KEY:** 0001776353

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 100 ESSEX RD.
- **CITY:** CHESTNUT HILL
- **STATE:** MA
- **ZIP:** 02467

## Ex-1

Exhibit 1

**<u>Transactions in Securities of the Issuer During the Past 60 Days</u>**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;<u>Nature of the Transaction</u> | &nbsp;&nbsp; Securities<br> <u>Acquired/(Disposed)</u> | &nbsp;&nbsp; <u>Price Per</u> <br> <u>Security ($)</u> | &nbsp;&nbsp; Date of<br> <u>Transaction</u> |

---

**<u>DANIEL S. FARB</u>**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(2500) | &nbsp;&nbsp;10.2556 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(3000) | &nbsp;&nbsp;10.0000 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(3000) | &nbsp;&nbsp;10.0301 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(3000) | &nbsp;&nbsp;10.1000 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(3000) | &nbsp;&nbsp;10.1175 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(3000) | &nbsp;&nbsp;10.2028 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Short Sale of Common Stock | &nbsp;&nbsp;(1000) | &nbsp;&nbsp;11.3594 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Short Sale of Common Stock | &nbsp;&nbsp;(3520) | &nbsp;&nbsp;11.1549 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Purchase to Cover Short Sale of Common Stock | &nbsp;&nbsp;1000 | &nbsp;&nbsp;11.2456 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Purchase to Cover Short Sale of Common Stock | &nbsp;&nbsp;3520 | &nbsp;&nbsp;11.1814 | &nbsp;&nbsp;08/04/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;1000 | &nbsp;&nbsp;9.0000 | &nbsp;&nbsp;08/07/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;500 | &nbsp;&nbsp;8.9200 | &nbsp;&nbsp;08/07/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;2000 | &nbsp;&nbsp;9.3670 | &nbsp;&nbsp;08/11/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;500 | &nbsp;&nbsp;9.6000 | &nbsp;&nbsp;08/11/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(1000) | &nbsp;&nbsp;9.3000 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(364) | &nbsp;&nbsp;9.1000 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(300) | &nbsp;&nbsp;9.3100 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(300) | &nbsp;&nbsp;9.2100 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(30) | &nbsp;&nbsp;9.4100 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(3) | &nbsp;&nbsp;9.5000 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(1) | &nbsp;&nbsp;9.5800 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(1) | &nbsp;&nbsp;9.4000 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(1) | &nbsp;&nbsp;9.3000 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(1900) | &nbsp;&nbsp;9.3241 | &nbsp;&nbsp;08/21/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(5000) | &nbsp;&nbsp;9.5000 | &nbsp;&nbsp;08/22/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(5000) | &nbsp;&nbsp;9.2500 | &nbsp;&nbsp;08/22/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(923) | &nbsp;&nbsp;9.5663 | &nbsp;&nbsp;08/25/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(2794) | &nbsp;&nbsp;9.3000 | &nbsp;&nbsp;08/25/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(2577) | &nbsp;&nbsp;10.1718 | &nbsp;&nbsp;08/25/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;12371 | &nbsp;&nbsp;9.0047 | &nbsp;&nbsp;08/25/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;9749 | &nbsp;&nbsp;8.9670 | &nbsp;&nbsp;08/26/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;462 | &nbsp;&nbsp;8.9200 | &nbsp;&nbsp;09/02/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(16949) | &nbsp;&nbsp;6.9923 | &nbsp;&nbsp;09/03/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;13418 | &nbsp;&nbsp;8.3744 | &nbsp;&nbsp;09/03/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(19051) | &nbsp;&nbsp;6.1405 | &nbsp;&nbsp;09/04/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;9831 | &nbsp;&nbsp;4.4396 | &nbsp;&nbsp;09/04/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;26169 | &nbsp;&nbsp;4.5172 | &nbsp;&nbsp;09/05/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;36000 | &nbsp;&nbsp;4.5353 | &nbsp;&nbsp;09/08/2025 |
| &nbsp;&nbsp;Sale of Common Stock | &nbsp;&nbsp;(2000) | &nbsp;&nbsp;4.9272 | &nbsp;&nbsp;09/10/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;3000 | &nbsp;&nbsp;4.7585 | &nbsp;&nbsp;09/10/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;62800 | &nbsp;&nbsp;5.5040 | &nbsp;&nbsp;09/12/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;1800 | &nbsp;&nbsp;5.2800 | &nbsp;&nbsp;09/15/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;200 | &nbsp;&nbsp;5.2500 | &nbsp;&nbsp;09/15/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;10000 | &nbsp;&nbsp;5.2600 | &nbsp;&nbsp;09/15/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;1000 | &nbsp;&nbsp;5.1820 | &nbsp;&nbsp;09/17/2025 |
| &nbsp;&nbsp;Purchase of Common Stock | &nbsp;&nbsp;4000 | &nbsp;&nbsp;5.2007 | &nbsp;&nbsp;09/17/2025 |

---

## Exhibit 99.4

Exhibit 99.4

**<u>JOINT FILING AND SOLICITATION AGREEMENT</u>**

WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Artelo Biosciences, Inc., a Nevada corporation (the "Company"); and

WHEREAS, Daniel Farb ("Mr. Farb") and Scott Pomfret (the "Nominee" and together with Mr. Farb, the "Group") wish to form a group for the purpose of (i) seeking representation on the Board of Directors of the Company (the "Board") at the 2025 annual meeting of stockholders of the Company (including any other meeting of stockholders held in lieu thereof, and any adjournments, postponements, reschedulings or continuations thereof, the "Annual Meeting"), (ii) soliciting proxies for the election of certain persons nominated for election to the Board at the Annual Meeting (including those nominated by or on behalf of Mr. Farb), (iii) taking all other action necessary to achieve the foregoing and (iv) taking any other actions the Group determines to undertake in connection with their respective investment in the Company (collectively, the "Purposes").

NOW, IT IS AGREED, this 18th day of September 2025 by the parties hereto:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the undersigned agrees to the joint filing on behalf of each of them of statements on Schedule 13D, and any amendments thereto, with respect to the securities of the Company to the extent required by applicable law. Each member of the Group shall be responsible for the accuracy and completeness of his own disclosure therein, and shall not be responsible for the accuracy and completeness of the information concerning the other members of the Group, unless such member knows or has reason to know that such information is inaccurate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. So long as this agreement is in effect, the Nominee agrees to provide Mr. Farb advance written notice prior to effecting any purchase, sale, acquisition or disposition of any securities of the Company which the Nominee has, or would have, direct or indirect beneficial ownership so that Mr. Farb has an opportunity to review the potential implications of any such transaction in the securities of the Company and pre-clear any such potential transaction in the securities of the Company by the Nominee. The Nominee agrees that he shall not undertake or effect any purchase, sale, acquisition or disposition of any securities of the Company without the prior written consent of Mr. Farb. For purposes of this agreement, the term "beneficial ownership" shall have the meaning of such term set forth in Rule 13d-3 under the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. So long as this agreement is in effect, each of the undersigned shall provide written notice to Olshan Frome Wolosky LLP ("Olshan") and Mr. Farb of any changes to his ownership of securities of the Company by 4:30 PM Eastern Time on the date of any such change in ownership of securities of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Each of the undersigned agrees to form the Group for the Purposes as set forth above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Mr. Farb shall have the right to pre-approve all expenses incurred in connection with the Group's activities and agrees to pay directly all such pre-approved expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Each of the undersigned agrees that any filing with the Securities and Exchange Commission, press release or other communication proposed to be made or issued by the Group or any member of the Group in connection with the Group's activities set forth in Section 4 shall be as directed by Mr. Farb.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. The relationship of the parties hereto shall be limited to carrying on the business of the Group in accordance with the terms of this agreement. Such relationship shall be construed and deemed to be for the sole and limited purpose of carrying on such business as described herein. Nothing herein shall be construed to authorize any party to act as an agent for any other party, or to create a joint venture or partnership, or to constitute an indemnification. Except as provided in Section 2 and Section 3, nothing herein shall restrict any party's right to purchase or sell securities of the Company, as he deems appropriate, in his sole discretion, provided that all such purchases and sales are made in compliance with all applicable securities laws and the provisions of this agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. This agreement may be executed in two or more counterparts, which together shall constitute a single agreement. Any signature to this agreement transmitted by facsimile transmission, by electronic mail in "portable document format" (".pdf") form or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document shall have the same effect as physical delivery of the paper document bearing the original signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. This agreement is governed by and will be construed in accordance with the laws of the State of New York. In the event of any dispute arising out of the provisions of this agreement or their investment in the Company, the parties hereto consent and submit to the exclusive jurisdiction of the United States District Court for the District of Massachusetts located in Boston, Massachusetts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. The parties' rights and obligations under this agreement (other than the rights and obligations set forth in Section 5 and Section 9, which shall survive any termination of this agreement) shall terminate upon the earlier to occur of (i) the certification of the results of the Annual Meeting or (ii) Mr. Farb providing written notice of termination to the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. Each party hereby waives the application of any law, regulation, holding, or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. The terms and provisions of this agreement may not be modified, waived or amended without the written consent of each of the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. Each party acknowledges that Olshan shall act as counsel for both the Group and Mr. Farb relating to their investment in the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. Each party hereby agrees that this agreement shall be filed as an exhibit to a Schedule 13D pursuant to Rule 13d-1(k)(1)(iii) under the Exchange Act.

IN WITNESS WHEREOF, the parties hereto have caused this agreement to be executed as of the day and year first above written.

---

| |
|:---|
| &nbsp;&nbsp; /s/ Daniel Farb |
| &nbsp;&nbsp;DANIEL FARB |

---

---

| |
|:---|
| &nbsp;&nbsp; /s/ Scott Pomfret |
| &nbsp;&nbsp;SCOTT POMFRET |

---

## Exhibit 99.5

Exhibit 99.5

**POWER OF ATTORNEY**

Know all by these presents, that the undersigned hereby constitutes and appoints Daniel Farb as the undersigned's true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned's beneficial ownership of, or participation in a group with respect to, securities of Artelo Biosciences, Inc., a Nevada corporation (the "Company"), directly or indirectly beneficially owned by Daniel Farb or any of his affiliates or members of his Schedule 13D group, if any (collectively, the "Group"), and (ii) any potential proxy solicitation that may be pursued by the Group to elect a slate of director nominees to the board of directors of the Company at the 2025 annual meeting of stockholders of the Company, including any adjournments or postponements thereof (the "Solicitation"). Such action shall include, but not be limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. if applicable, executing for and on behalf of the undersigned a Schedule 13D, and amendments thereto, filed by the Group that are required to be filed under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, in connection with the undersigned's beneficial ownership of, or participation in a group with respect to, securities of the Company or the Solicitation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. if applicable, executing for and on behalf of the undersigned all Forms 3, 4 and 5 required to be filed under Section 16(a) of the Exchange Act, and the rules thereunder, in connection with the undersigned's beneficial ownership of, or participation in a group with respect to, securities of the Company or the Solicitation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. executing for and on behalf of the undersigned all Group Agreements or similar documents pursuant to which the undersigned shall agree to be a member of the Group;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. performing any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such document, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. taking any other action of any type whatsoever in connection with the Solicitation, including entering into any settlement agreement, that in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 13(d), Section 16 or Section 14 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer a member of the Group unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of September 2025.

---

| |
|:---|
| &nbsp;&nbsp; /s/ Scott D. Pomfret |
| &nbsp;&nbsp;**SCOTT D. POMFRET** |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**ARTELO BIOSCIENCES, INC.**

*(Name of Issuer)*

**Common Stock, $0.001 par value per share**

*(Title of Class of Securities)*

**04301G607**

*(CUSIP Number)*

**RYAN NEBEL**<br>OLSHAN FROME WOLOSKY LLP<br>1325 Avenue of the Americas<br>New York NY 10019<br>212-451-2300

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/12/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **04301G607** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Farb Daniel Stuart** | Name of reporting person<br>**Farb Daniel Stuart** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ISRAEL** | Citizenship or place of organization<br>**ISRAEL** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**153000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**153000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**153000.00** | Aggregate amount beneficially owned by each reporting person<br>**153000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.8%** | Percent of class represented by amount in Row (11)<br>**9.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.001 par value per share

**(b) Name of Issuer:**
ARTELO BIOSCIENCES, INC.

**(c) Address of Issuer's Principal Executive Offices:**
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA, 92075

**Item 4. Purpose of Transaction**

The Reporting Person purchased the Shares based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Person may endeavor to increase or decrease his position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable.

On September 19, 2025, the Reporting Person delivered a letter to the Issuer nominating a slate of highly qualified director candidates, including Daniel S. Farb and Scott D. Pomfret (collectively, the "Nominees"), for election to the Board of Directors (the "Board") at the Issuer's 2025 annual meeting of stockholders (the "Annual Meeting"). As evidenced by their biographies below, the Nominees are well qualified to serve on the Board.

Daniel S. Farb currently serves as the President and Managing Member of each of Mill Pond Capital, LLC (f/k/a Mill Pond Capital Corporation), an investment firm, and Big Mill Pond Capital Management, LLC, an investment firm, since 2019. Previously, Mr. Farb served as Partner and Managing Director of Highfields Capital Management LP ("Highfields Capital"), a Boston-based hedge fund, from 2001 to 2019. Earlier in his career, Mr. Farb worked at Goldman, Sachs & Co., a global investment bank and financial services firm, in the Mergers & Acquisitions and Principal Investment Groups. Currently, Mr. Farb serves on the Board of Directors of Advantage Energy Ltd. (TSX: AAV), a Canadian oil and natural gas company, since March 2025. Previously, Mr. Farb served as a member of the Boards of Directors of PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a clinical-stage biotechnology company, from August 2022 to December 2022, and Meg Energy Corp. (TSX: MEG), a Canadian oil and gas company, from 2017 to 2018. Mr. Farb earned his MBA from Harvard Business School and a Bachelor of Commerce Degree from McGill University. The Reporting Person believes that Mr. Farb's extensive experience in investment management and capital markets, public company board experience and perspective as a significant stockholder of the Issuer make him well-qualified to serve on the Board.

Scott D. Pomfret currently serves as the Founder and Sole Member of Regulatory Counsel LLC, a company providing legal, regulatory and compliance advisory services, since 2019. Mr. Pomfret also currently serves as a Senior Advisor to a number of companies, including Skematic, a company offering compliance management and workflow solutions, since November 2024; ShortWatch, Inc., a financial technology services company, since May 2024; Twin Oak ETF Company, an investment adviser that manages exchange-traded funds (ETFs), since August 2024; and Blue Heron Research Partners, an independent research firm that conducts qualitative due diligence for institutional investors, since May 2022. In addition, Mr. Pomfret currently serves as a member of the Advisory Committees of Liminality Capital Management LP, an investment firm, since June 2020, and Solel Capital Partners Master Fund, L.P., an investment fund, since 2019. Previously, Mr. Pomfret served as Regulatory Counsel and Chief Compliance Officer at Highfields Capital, an investment management firm, from 2011 to 2019. Prior to Highfields Capital, he served as Director, Financial Services Regulatory Practice, of PricewaterhouseCoopers LLP, a multinational professional services firm; as Senior Counsel and Branch Chief in the Division of Enforcement at the United States Securities and Exchange Commission, a federal regulatory agency, and as a Special Assistant United States Attorney; as a litigation Associate at Ropes & Gray, LLP, a global law firm; and as a Law Clerk for the U.S. Court of Appeals for the First Circuit. Mr. Pomfret currently serves as a member of the Board of Directors of Highfields Capital Ltd., an investment vehicle of Highfields Capital, since March 2020. Mr. Pomfret earned a Juris Doctor from University of Michigan Law School and a B.S. in Psychology and English from St. Lawrence University. The Reporting Person believes that Mr. Pomfret's extensive legal, regulatory and compliance experience across the capital markets industry and extensive experience advising boards of directors makes him well-qualified to serve on the Board.

The Reporting Person has engaged, and intends to continue to engage, in communications with management and the Board of the Issuer, stockholders and other third parties regarding potential opportunities to unlock stockholder value at the Issuer. The Reporting Person previously engaged in discussions with the Issuer and other current and/or potential stockholders of the Issuer regarding potential investments and financing transactions. The Reporting Person also previously discussed with management and others potential investments in cryptocurrencies, including Solana, and transactions in connection therewith that could result in an extraordinary corporate transaction, and may continue to do so. The Reporting Person is a party to the June 2025 SPA as further explained in Item 6 below.

The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Person intends to review his investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to his investment in the Issuer as he deems appropriate including, without limitation, engaging in additional communications and discussions with management and the Board, engaging in additional discussions and communications with stockholders of the Issuer or other third parties about the Issuer and the Reporting Person's investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capital allocation strategy, capitalization, ownership structure, Board structure (including Board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional Shares, selling some or all of his Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing his intention with respect to any and all matters referred to in Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The aggregate percentage of Shares reported owned by the Reporting Person is based upon 1,555,493 Shares outstanding as of September 16, 2025, as disclosed in the Issuer's Corporate Presentation issued on September 17, 2025 that is available on the Issuer's website.

As of the date hereof, the Reporting Person directly beneficially owns 153,000 Shares, constituting approximately 9.8% of the Shares outstanding.

In addition, as of the date hereof, the Reporting Person owns 11,299 warrants referencing 11,299 Shares, which have an exercise price of $10.00 per Share and expire in June 2030 (the "$10 Warrants"), and 3 warrants referencing 3 Shares, which have an exercise price of $5.82 per Share and expire in June 2030 (the "$5.82 Warrants" and together with the $10 Warrants, the "Warrants"). The Warrants are exercisable immediately, subject to the Beneficial Ownership Limitation (as defined below). A holder of the Warrants may not exercise any such Warrants to the extent that such exercise would result in the number of Shares beneficially owned by such holder and his or its affiliates exceeding 4.99% of the total number of Shares outstanding immediately after giving effect to the exercise, except that upon at least 61 days' prior notice from the holder to the Issuer, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of Shares outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation"). The Reporting Person's Beneficial Ownership Limitation is currently set at 4.99% and, accordingly, the Reporting Person cannot exercise the Warrants and does not beneficially own any of the Shares underlying the Warrants.

**(b)**
The Reporting Person has the sole power to vote or direct the vote and the sole power to dispose or to direct the disposition of the securities of the Issuer beneficially owned by him.

**(c)**
As further explained in Item 6 below, the Reporting Person received 22,595 Shares from the Issuer upon the exercise of all 22,598 of the $5.82 Warrants held by him pursuant to a notice of exercise delivered to the Issuer on July 23, 2025. Other than as set forth in the immediately preceding sentence, the transactions in the securities of the Issuer by the Reporting Person during the past 60 days are set forth in Exhibit 1 and are incorporated herein by reference. All of such transactions were effected in the open market unless otherwise noted therein.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

On June 24, 2025, the Reporting Person entered into a Securities Purchase Agreement with the Issuer and certain other investors (the "June 2025 SPA"). Pursuant to the June 2025 SPA, the Reporting Person purchased (i) 11,299 Shares, (ii) 22,598 of the $5.82 Warrants and (iii) 11,299 of the $10 Warrants for an aggregate purchase price of $70,000.00. Pursuant to the June 2025 SPA, the Issuer filed a Registration Statement with the SEC on Form S-1 on July 11, 2025, registering the resale of the Shares and Shares underlying the Warrants purchased by the Reporting Person (and the other investors). The June 2025 SPA contained customary representations, warranties and agreements by the Issuer, indemnification obligations of the Issuer and the Reporting Person (and the other investors), including for liabilities under the Securities Act of 1933, as amended, and other obligations of the parties.

A copy of the form of the June 2025 SPA, the $10 Warrant and the $5.82 Warrant are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and incorporated herein by reference.

On July 23, 2025, the Reporting Person delivered a notice of exercise with respect to all 22,598 of the $5.82 Warrants held by him and initiated a wire transfer to the Issuer in an amount equal to $131,520.36, which represents the exercise price of $5.82 multiplied by all 22,598 of the $5.82 Warrants held by him. The Reporting Person only received 22,595 Shares in connection with such exercise and requested delivery of the remaining 3 Shares pursuant to a letter dated September 15, 2025 upon discovering that they were never delivered. In response, on September 17, 2025, the Issuer's counsel advised that the 3 missing Shares would not be delivered and instead confirmed that the Issuer intends to wire the Reporting Person $17.46 (the exercise price of the 3 undelivered Shares).

On September 18, 2025, the Reporting Person and Mr. Pomfret entered into a Joint Filing and Solicitation Agreement (the "JFSA") in connection with the Annual Meeting, pursuant to which, among other things, (a) the parties agreed to form a group for the purposes of seeking representation on the Board at the Annual Meeting and taking all other action necessary or advisable to achieve the foregoing, including soliciting proxies for the election of certain persons nominated for election to the Board at the Annual Meeting, (b) Mr. Pomfret agreed not to undertake or effect any purchase, sale, acquisition or disposition of any securities of the Issuer without the prior written consent of the Reporting Person and (c) the Reporting Person agreed to bear all expenses incurred in connection with the group's activities. A copy of the JFSA is attached hereto as Exhibit 99.4 and incorporated herein by reference.

Mr. Pomfret has granted the Reporting Person a power of attorney (the "Power of Attorney") to execute certain SEC filings and other documents in connection with the solicitation of proxies from the Issuer's stockholders in connection with the Annual Meeting and any related transactions. A copy of the Power of Attorney is attached hereto as Exhibit 99.5 and incorporated herein by reference.

Other than as described herein, there are no contracts, arrangements, understandings or relationships between or among the Reporting Person and any other person with respect to the securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Farb Daniel Stuart

**Signature:** /s/ Daniel S. Farb

**Name/Title:** Daniel S. Farb

**Date:** 09/19/2025